Penetration of intravesical doxorubicin in human bladders

Cancer Chemotherapy and Pharmacology
M G WientjesJ L Au

Abstract

The bladder wall penetration kinetics of intravesical doxorubicin were examined in radical cystectomy patients, to provide insight into drug concentrations at target tumor sites. The dosing solution (40 mg/20 ml) was instilled just prior to the start of surgery and maintained for 60-115 min until just prior to bladder excision. The data showed considerable inter-patient variability in the peak plasma concentration (24-fold), urine concentration (7- fold), and tissue concentration (28-fold). The urine concentration at the time of tissue harvest was about 17% of the concentration in the dosing solution. This was due to the dilution by post-catheterization residual urine and urine produced during treatment. The doxorubicin concentration dropped by 32-fold across the urothelium, and declined semi-logarithmically with respect to depth in the capillary-perfused tissues beneath the urothelium with a 50% decrease over about 500 micromole. In three of six patients from whom tumor tissue was obtained, the doxorubicin concentration was higher than the adjacent non-tumor-bearing tissues of comparable tissue depth, whereas the reverse was seen in the remaining three tumors. The plasma concentrations were 0.02, 0.03, 0.05, 0.27, and 0.69% of...Continue Reading

Citations

Nov 12, 2010·Cancer Chemotherapy and Pharmacology·Antonia TsallasHelen Burt
Mar 29, 2008·Pharmaceutical Research·Zancong ShenJessie L-S Au
Aug 8, 2001·Journal of Controlled Release : Official Journal of the Controlled Release Society·J L AuM G Wientjes
Jan 5, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jessie L-S AuM Guill Wientjes
Aug 6, 2003·Critical Reviews in Oncology/hematology·Per-Uno Malmström
Apr 2, 1997·Journal of the National Cancer Institute·R L Dedrick, M F Flessner
Apr 20, 2001·Journal of the National Cancer Institute·J L AuUNKNOWN International Mitomycin C Consortium
Nov 11, 2010·Future Oncology·Ze LuJessie L-S Au
Sep 12, 2007·Journal of Pharmaceutical Sciences·Brent D WeinbergJinming Gao
Feb 17, 2015·Naunyn-Schmiedeberg's Archives of Pharmacology·Sung-Hyun KangRuss Chess-Williams
May 26, 2017·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Andrew S MikhailBradford J Wood
Sep 1, 1997·Seminars in Surgical Oncology·R A Badalament, R N Farah
Jun 13, 2003·Cancer Chemotherapy and Pharmacology·Tina LeakakosScott Goodwin
Dec 1, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ze LuM Guill Wientjes
Jun 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·M Guillaume WientjesJessie L-S Au
Sep 29, 2021·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Iris S G BrummelhuisEgbert Oosterwijk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.